Mylan CEO Heather Bresch is scheduled to testify before a US House of Representatives committee investigating the price of EpiPen auto-injectors which have surged to over $600 per pair in recent months.
The Committee on Oversight and Government Reform announced yesterday that Bresch will appear before the committee to testify on September 21. Rep Elijah Cummings, the ranking Democrat on the committee from Maryland, called for the hearing last month.
“There is justified outrage from families and schools across the country struggling to afford the high cost of EpiPens. We look forward to receiving answers next week from Mylan about its dramatic price hike for this life-saving medication,” said Cummings in a joint statement with Rep Jason Chaffetz (R-Utah). “Our goal is to work together to ensure that critical medications, like the EpiPen, are accessible and affordable for all of our constituents.”
Records regarding Mylan’s revenues, costs, and money garnered from government programs related to sales of EpiPen since 2007 were requested by the committee and the company has indicated it will begin providing the documents this week.
